Sun Pharmaceutical Industries today said its unit has received US health regulator's approval for generic docetaxel injection, used in treating cancer, in the American market.
The company's subsidiary -- Sun Pharma Advanced Research Company -- has received abbreviated new drug approval from US Food and Drug Administration for Docefrez in strength of 20 mg/vial and 80 mg/vial, Sun Pharma said in a statement.
The company's product is indicated for metastatic breast cancer, lung cancer and hormone refractory metastatic prostate cancer, it added.
Shares of Sun Pharma were today trading at Rs 443 on the Bombay Stock Exchange in late afternoon trade, down 1.14% from the previous close.
